Iovance Biotherapeutics, Inc.

NasdaqGM:IOVA Rapport sur les actions

Capitalisation boursière : US$3.4b

Iovance Biotherapeutics Résultats passés

Passé contrôle des critères 0/6

Iovance Biotherapeutics's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 106.9% per year.

Informations clés

-18.9%

Taux de croissance des bénéfices

-5.5%

Taux de croissance du BPA

Biotechs Croissance de l'industrie17.0%
Taux de croissance des recettes106.9%
Rendement des fonds propres-57.3%
Marge nette-1,343.3%
Prochaine mise à jour des résultats07 Nov 2024

Mises à jour récentes des performances passées

Recent updates

Iovance Biotherapeutics: Moving To The Next Phase

Oct 03

Iovance Therapeutics: Historic Product, Tough Commercial Outlook

Sep 06

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Aug 11
Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)

Aug 11

Iovance Biotherapeutics: Amtagvi Launch Continues Upward

Jun 26

Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi

May 10

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Apr 09

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Mar 25

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Feb 20

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Jan 19

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

Sep 27

Iovance submits rolling license application to FDA for skin cancer treatment lifileucel

Aug 25

Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Aug 25
Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss

Aug 04

Iovance: TIL Cell Therapy Set To Prove Itself

Jul 11

Iovance: Onward To Approval

Apr 20

Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside

Mar 25

Ventilation des recettes et des dépenses

Comment Iovance Biotherapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NasdaqGM:IOVA Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 2433-440128317
31 Mar 242-450110341
31 Dec 231-444107344
30 Sep 231-433103337
30 Jun 230-419104322
31 Mar 230-412109309
31 Dec 220-396104295
30 Sep 220-390101290
30 Jun 220-37694283
31 Mar 220-35887271
31 Dec 210-34284259
30 Sep 210-31176236
30 Jun 210-28471214
31 Mar 210-26566201
31 Dec 200-26060202
30 Sep 200-25555204
30 Jun 200-24649202
31 Mar 200-23046192
31 Dec 190-19841166
30 Sep 190-16738139
30 Jun 190-15135126
31 Mar 190-13431111
31 Dec 180-12428100
30 Sep 180-1172693
30 Jun 180-1052582
31 Mar 180-982376
31 Dec 170-922172
30 Sep 170-821361
30 Jun 170-1281753
31 Mar 170-1162038
31 Dec 160-1021727
30 Sep 160-952521
30 Jun 160-341817
31 Mar 160-291217
31 Dec 150-281215
30 Sep 150-241014
30 Jun 150-19109
31 Mar 150-1596
31 Dec 140-1284
30 Sep 140-2772
30 Jun 140-3472
31 Mar 140-3561

Des revenus de qualité: IOVA is currently unprofitable.

Augmentation de la marge bénéficiaire: IOVA is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: IOVA is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.

Accélération de la croissance: Unable to compare IOVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: IOVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement des fonds propres

ROE élevé: IOVA has a negative Return on Equity (-57.28%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé